AstraZeneca stock steadies as FY2026 EPS forecast is trimmed but outlook stays positive
Published on 09/01/2026 at 07:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca plc (ISIN US6549022043) stock is trading in the mid-$160 range as of August 31, 2026, with analysts projecting double-digit earnings per share for fiscal 2026 even after a small downward revision to forecasts.
The latest research update dated August 31, 2026, highlights a modest cut to the company’s FY2026 EPS estimate, while pointing to a strong recent quarter where earnings and revenue exceeded expectations, reinforcing confidence in the long-term story for the biopharmaceutical group.
For investors, the key takeaway is that AstraZeneca remains an earnings growth story, with current forecasts still pointing to EPS above $10 in fiscal 2026 and a consensus price target comfortably ahead of the present share price.
Fresh EPS forecast cut and consensus view
A detailed analyst summary published on August 31, 2026, reports that one research house has reduced its FY2026 earnings forecast for AstraZeneca to $10.14 per share from $10.25, a cut of $0.11 that leaves the estimate just below the broader analyst consensus of $10.19 for the year. This coverage also notes that the consensus price target across analysts stands at $206.67, implying upside from the latest trading level.
Within the same summary, analyst sentiment is characterized as supportive, with the stock carrying an overall rating that reflects more Buy recommendations than Hold or Sell calls. While individual views range from positive to cautious, the aggregate message is that AstraZeneca is expected to grow earnings meaningfully over the next several years, and that the current share price does not fully reflect that trajectory.
The trimmed FY2026 EPS estimate underscores that forecasts are dynamic and respond to pipeline progress, competition, and pricing, yet the difference between $10.25 and $10.14 is small relative to the absolute level of earnings expected, keeping the growth narrative intact.
Latest quarterly beat and revenue growth
The same analyst report points to AstraZeneca’s most recently reported quarter, in which the company delivered earnings per share of $2.63 versus a consensus expectation of $2.50, an upside surprise of $0.13 per share that underlines operational strength. The quarterly review states that net revenue in that period reached $15.38 billion, representing year-over-year growth of 6.4%, while the prior-year quarter had recorded EPS of $2.17.
That combination of double-digit EPS and mid-single-digit revenue growth suggests that AstraZeneca has been able to expand margins and scale its portfolio, particularly in oncology and cardiovascular therapies, even as pricing pressures and competition remain key themes in the sector. The move from $2.17 to $2.63 in quarterly EPS compares favorably against many large-cap peers, indicating strong operating leverage and disciplined cost management.
From a balance-sheet perspective, the same analysis notes a market capitalization of $252.53 billion, supported by a price-to-earnings ratio of 24.34, a price/earnings-to-growth (PEG) ratio of 1.41, and a beta of 0.26, pointing to relatively low share price volatility compared with the broader market. These metrics show investors paying a premium multiple for an established pipeline and cash generation, while still receiving a discount relative to consensus valuation estimates.
Valuation, trading range, and technical context
On the New York Stock Exchange, AstraZeneca’s American depositary shares most recently opened at $162.83, according to the same August 31, 2026 performance snapshot, placing the stock below its consensus price target of $206.67 and within a well-defined 12-month trading range.
The shares have a twelve-month low of $145.79 and a twelve-month high of $212.71, implying that the latest $162.83 level sits $17.04 above the low and $49.88 below the high, which highlights both the room for potential recovery and the volatility already experienced over the past year. With a 50-day moving average of $171.23 and a 200-day moving average of $184.72, the stock currently trades below both moving averages, signaling a period of consolidation after earlier strength.
Liquidity metrics include a current ratio of 0.89 and a quick ratio of 0.67, indicating that short-term assets are slightly below short-term liabilities, a common profile for large pharmaceutical companies with predictable cash flows and access to capital. A debt-to-equity ratio of 0.47 shows moderate leverage, giving the company scope to invest in R&D and business development while keeping overall gearing at a manageable level.
Analyst ratings and earnings outlook
The analyst overview compiled in late August notes that multiple firms cover AstraZeneca with ratings spanning Buy, Hold, and Sell, but that the majority of recommendations are on the Buy side, resulting in an overall consensus view that remains positive.
Within that coverage, firms that recently initiated or updated views have pointed to AstraZeneca’s focus on oncology and cardiovascular risk reduction as key drivers of long-term earnings growth, while also flagging the potential impact of patent expiries and competitive launches in certain indications. Despite these industry-wide risks, the consensus EPS estimate of $10.19 for FY2026 reflects expectations of continued revenue expansion and margin resilience.
The modest downgrade of one firm’s FY2026 EPS forecast from $10.25 to $10.14 is therefore better seen as a fine-tuning within an established growth trajectory rather than a fundamental shift. When compared with the recent quarterly EPS of $2.63 and prior-year EPS of $2.17, the full-year numbers imply that AstraZeneca could sustain elevated profitability levels if its pipeline remains on track.
Business portfolio and representative product
AstraZeneca’s strategy centers on specialty medicines in oncology, cardiovascular, renal and metabolism, and respiratory and immunology, aiming to deliver therapies with strong clinical benefit and reimbursement support. The product mix includes targeted cancer drugs, biologics, and small molecules designed to modify disease progression or improve outcomes versus standard-of-care.
One representative product is goserelin acetate, marketed in many regions under the brand name Zoladex as a long-acting injectable for hormone-sensitive cancers such as prostate cancer and certain breast cancers. Goserelin is a gonadotropin-releasing hormone (GnRH) agonist that reduces hormone levels to help slow or stop tumor growth in hormone-dependent malignancies.
As a branded therapy available in multiple dosage strengths and formulations, Zoladex contributes to AstraZeneca’s oncology portfolio revenue and illustrates the company’s position in long-established, clinically validated treatment paradigms alongside newer immuno-oncology and targeted agents.
Stock level and investor angle
As of August 31, 2026, AstraZeneca’s New York-listed shares were trading at $162.83, positioned below recent moving averages and well under the consensus price target of $206.67, indicating that the stock price does not fully reflect the earnings growth embedded in FY2026 forecasts.
For investors, the current valuation combines a large-cap biopharmaceutical profile, a $252.53 billion market capitalization, and a twelve-month range between $145.79 and $212.71, with the most recent quarter showing EPS of $2.63 and revenue of $15.38 billion, up 6.4% year over year. That mix of scale, growth, and pipeline exposure helps explain why consensus estimates still point to FY2026 EPS above $10 even after minor forecast adjustments.
Fact box
Company: AstraZeneca plc
ISIN: US6549022043
Ticker: AZN
Exchange: New York Stock Exchange (ADR)
Price (as of August 31, 2026, opening): $162.83 USD
Market cap: $252.53 billion (as of the latest performance snapshot)
Sector / Industry: Health care / Pharmaceuticals and biotechnology
Index membership: FTSE 100 (primary London listing)
